StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.24+0.24 (+12.00%)

Close on Nov 18, 2026Market cap $101.35MP/E –Yield –

Genelux operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Genelux's operating income for the twelve months ending Jun 30, 2026 was -$36.42M. For fiscal 2025 it was -$33.21M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$33.21M–
FY2024Dec 31, 2024-$31.70M–
FY2023Dec 31, 2023-$24.17M–
FY2022Dec 31, 2022-$3.01M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.65M–
Q1 FY2026Mar 31, 2026-$9.17M–
Q4 FY2025Dec 31, 2025-$9.41M–
Q3 FY2025Sep 30, 2025-$8.19M–
Q2 FY2025Jun 30, 2025-$7.79M–
Q1 FY2025Mar 31, 2025-$7.82M–
Q4 FY2024Dec 31, 2024-$9.75M–
Q3 FY2024Sep 30, 2024-$6.94M–
Q2 FY2024Jun 30, 2024-$6.89M–
Q1 FY2024Mar 31, 2024-$8.12M–
Q4 FY2023Dec 31, 2023-$7.00M–
Q3 FY2023Sep 30, 2023-$5.31M-183.7%
Q2 FY2023Jun 30, 2023-$5.40M–
Q1 FY2023Mar 31, 2023-$6.46M–
Q4 FY2022Dec 31, 2022-$3.09M–
Q3 FY2022Sep 30, 2022$6.34M–
Q2 FY2022Jun 30, 2022-$2.80M–
Q1 FY2022Mar 31, 2022-$3.46M–

More Genelux figures

See a number that looks wrong?